

Notice under section 708A(5)(e) of the Corporations Act 2001

This notice is given by Bluechiip Limited (**Bluechiip** or the **Company**) (**ASX: BCT**), under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Bluechiip refers to its announcement on 5 May 2023 regarding the successful placement to raise \$2.2 million (before costs) (**Placement**). Pursuant to the Appendix 2A released today, Bluechiip has issued 84,000,000 fully paid ordinary shares (**Shares**) in the capital of the Company to institutional, sophisticated and professional investors at an issue price of A\$0.025 per Share pursuant to the Placement. The issue of \$100,000 worth of Shares to a related party, being the Company's Chairman Mr Iain Kirkwood who participated in the Placement, is subject to shareholder approval which will be sought at the Company's next general meeting.

The Corporations Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Corporations Act. By giving this notice, a sale of the Shares noted above will fall within the exemption in section 708A(5) of the Corporations Act and will be able to be traded immediately.

The Company also hereby provides notification under the *ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547* (**ASIC Instrument**). The Company is offering Shares under a Share Purchase Plan (**SPP**) targeting raising a further \$300,000 (before costs). The SPP will be offered in accordance with the ASIC Instrument and a SPP offer booklet will be dispatched to eligible shareholders of the Company.

For the purposes of section 708A(6) of the Corporations Act, and the ASIC Instrument, the Company hereby provides the following notice that:

- a) the Company issued Shares under the Placement, and will make offers to issue Shares under the SPP, without disclosure to investors under Part 6D.2 of the Corporations Act;
- b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- c) as at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. section 674 and section 674A of the Corporations Act; and
- d) as at the date of this notice, there is no information required to be disclosed which is 'excluded information' within the meanings of section 708A(7) and 708A(8) of the Corporations Act.

END.

Authorised for release by the Bluechiip Limited Board

For more information, please contact:

Corporate enquiries

Andrew McLellan
Managing Director / CEO
Ph: +61 457 823 470
andrew.mclellan@bluechiip.com

Media

Richard Allen
Ph: +61 403 493 049
Oxygen Financial PR
richard@oxygenpr.com.au

About Bluechiip Limited

Bluechiip understands that every biological sample – stem cells, blood, eggs, sperm and other biospecimens – is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced sample management solution is the only one that provides sample temperature with ID in cryogenic environments, driving productivity and improving quality. Bluechiip's solution delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product is easily identified and critical information, such as sample temperature, detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip® Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip listed on the ASX in June 2011. Since then, we have significantly developed our technology. Today it has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

Further information is available at www.bluechiip.com